Who uses Element AVITI?
AVITI is a benchtop short-read sequencer built on its own chemistry, avidity sequencing. It's made by Element Biosciences. 447 bioRxiv and medRxiv preprints since April 2025 say they used AVITI, 171 in the last 6 months. Updated daily (as of Nov 16)
Is AVITI use still growing?
Yes: 171 preprints used AVITI in Jun–Nov 2026, +50% vs the previous year as a share of all preprints. This is faster than short-read sequencers overall (+8%).
The last bar is the quarter so far. The % over each year compares it with the year before, as a share of all preprints.
How does AVITI compare with other short-read sequencers?
AVITI is fourth, with 6% of their uses in Jun–Nov 2026, up from 4% the year before. NovaSeq X leads with 44%.
Which institutions use AVITI most?
The institutions using AVITI most are University of Lausanne, Columbia University and École Polytechnique Fédérale de Lausanne.
Institutions
University of Lausanne18
Columbia University16
École Polytechnique Fédérale de Lausanne12
University of California, Davis12
University of Minnesota10
Where the labs are
The lab's institution and country are the corresponding author's.
Rival platforms, head to head
Latest preprints using AVITI
Who started using AVITI recently?
61 institutions posted their first preprint using AVITI since April 2025 in the last 6 months, including INRAE, VIB and Leipzig University.
INRAEAug 17, 2026
- VIBOct 16, 2026
Leipzig UniversityJun 2, 2026
Emory UniversityJun 4, 2026
California State University, NorthridgeJun 4, 2026
Auburn UniversityJun 8, 2026
Max Planck Institute for Terrestrial MicrobiologyJun 9, 2026
Institute of Science TokyoJun 10, 2026
Institute for Research in Immunology and CancerJun 15, 2026
Murdoch Children’s Research InstituteJun 17, 2026
An institution counts as new when its first preprint using AVITI since April 2025 was posted in the last 6 months; the date is that first preprint.
What do labs use alongside AVITI?
Preprints using AVITI most often also use Chromium, NextSeq and NovaSeq X. The count is preprints using both.
What is AVITI used for?
Preprints using AVITI are most often in genomics, microbiology and molecular biology.
Fields
Genomics 73Microbiology 68Molecular biology 40Cancer biology 30Immunology 27Cell biology 26
Where the work was published
- Nature Communications6
- G3: Genes, Genomes, Genetics4
- Proceedings of the National Academy of Sciences4
- Cell3
- ISME Communications3
- Journal of the American Heart Association2
How we count which preprints use each platform
An AI model reads each preprint in full — its text, its tables and its supplementary files — and lists the products the authors used. A preprint counts for a platform when that record says the lab used it in this work, not when it only analyzed data others made with it or only mentioned it. Each preprint counts once, by its first version, if it was first posted on bioRxiv or medRxiv in April 2025 or later. We read new preprints within days of posting, so the newest ones (through Nov 16, 2026) are already counted, but those days are not complete yet. Six-month counts and growth figures stop at Nov 12, 2026, the last day nearly every preprint has been read, and charts draw a quarter that is still being counted in a paler color. A preprint that used two platforms counts for both. Each title links to the preprint on bioRxiv or medRxiv; we show no preprint text and no author names. Updated daily, most recently on Nov 16, 2026.